Governance Negative

2026-07-13 18:28

CRITICAL RED FLAG DETECTED

- Mr. Rajesh Shashikant Dalal will not seek re-appointment as a Non-Executive Independent Director, effective August 24, 2026. - He will also cease to be Chairperson of the Nomination and Remuneration Committee and Stakeholders Relationship Committee, and a member of the Audit Committee.

Governance Neutral

2026-06-26 15:11

- Board of Directors approved allotment of 1,475 Equity Shares of face value ₹10/- each under the Entero Employee Stock Option Plan 2023. - Approved revised tenure for re-appointment of Mr. Rajesh Shashikant Dalal and Ms. Sandhya Gadkari Sharma as Non-Executive Independent Directors for a second 4-year term (August 25, 2026, to August 24, 2030), subject to shareholder approval.

Governance Neutral

2026-06-26 15:11

- Board meeting held on June 26, 2026. - Approved allotment of 1,475 equity shares under the Entero Employee Stock Option Plan 2023. - Approved revised tenure for reappointment of Mr. Rajesh Shashikant Dalal and Ms. Sandhya Gadkari Sharma as Non-Executive Independent Directors, subject to shareholder approval. Mr. Sujesh Vasudevan's tenure remains unchanged.

Governance Neutral

2026-06-26 15:00

- Board meeting on June 26, 2026, approved allotment of 1,475 equity shares under ESOP 2023. - Approved revised 4-year reappointment tenure for Independent Directors Mr. Rajesh Shashikant Dalal and Ms. Sandhya Gadkari Sharma; Mr. Sujesh Vasudevan's tenure unchanged.

Governance Neutral

2026-06-26 14:59

- Board Meeting held on June 26, 2026. - Approved allotment of 1,475 equity shares under the Entero Employee Stock Option Plan 2023. - Approved revised tenure for re-appointment of Mr. Rajesh Shashikant Dalal and Ms. Sandhya Gadkari Sharma as Non-Executive Independent Directors, subject to shareholder approval.

Governance Neutral

2026-06-26 14:59

- Board Meeting on June 26, 2026, approved allotment of 1,475 Equity Shares under ESOP 2023. - Revised tenure for re-appointment of Mr. Rajesh Shashikant Dalal and Ms. Sandhya Gadkari Sharma as Non-Executive Independent Directors for a second four-year term. - Mr. Sujesh Vasudevan's tenure remains unchanged.

Ownership Neutral

2026-06-23 17:10

- The trading window for dealing in company securities will close from July 01, 2026, for designated persons. - It will remain closed until 48 hours after the declaration of Unaudited Financial Results for the quarter ended June 30, 2026.

Governance Neutral

2026-06-12 19:06

- Mr. Kevin Rohitbhai Daftary, Nominee Director representing "Prasid Uno Family Trust", resigned from the Board effective June 12, 2026. - Reason cited: increased professional responsibilities and commitments, with no other material reasons confirmed. - The vacancy will be filled upon fresh nomination from the Trust.

Governance Neutral

2026-06-11 18:27

- Board Meeting held on June 11, 2026, approved the allotment of 3,420 equity shares to eligible employees under the ESOP Plan 2023. The Board also noted the grant of fresh 17,500 Employee Stock Options under the same plan.

Governance Positive

2026-06-11 18:21

- Board approved allotment of 3,420 equity shares at an exercise price of Rs. 804 per share to eligible employees under the ESOP Plan 2023. - Board also granted 17,500 fresh Employee Stock Options under the existing ESOP Plan 2023.

Governance Neutral

2026-06-11 18:10

- Board of Directors approved the allotment of 3,420 equity shares (₹10/- face value, ₹804 exercise price) to employees under the ESOP Plan 2023, upon option exercise. - The Board also approved the grant of fresh 17,500 Employee Stock Options under the existing Entero Employee Stock Option Plan 2023.

Business Update Positive

2026-06-02 15:02

- FY27 consolidated revenue guidance of 23% YoY growth (excluding new acquisitions). - FY27 EBITDA margin guidance of 5%. - Aim to deliver EBITDA to operating cash flow conversion ratio of at least 50% for FY27. - MedTech segment currently contributes over ₹1,000 crores annualized revenue, with a target to reach 20% of total revenue in 2-3 years, driven by higher margins from commercial roles. - Focus for the next 6-8 months is on organic growth and integrating recent acquisitions, with no new acquisitions included in FY27 guidance. - Gross margin expansion is expected due to scale-led purchasing and playing a more commercial role. - Finance costs are expected to stabilize in the near term and reduce subsequently.

Routine Neutral

2026-05-28 23:24

New Filing detected. See link for details.

Business Update Neutral

2026-05-26 15:30

Entero Healthcare Solutions Limited announced the uploading of the audio recording for its Investors/Analyst Earnings Call/Conference Call held for the Audited Financial Results for the Quarter and Year ended March 31, 2026. The recording is accessible via a provided link, and the transcript will be shared with stock exchanges and uploaded on the company's website shortly.

Financials Positive

2026-05-25 21:46

Standalone Revenue ₹78.93Cr vs ₹72.30Cr (▲9.2% YoY). Standalone EBITDA swung to a profit of ₹17.42Cr from a loss of ₹33.15Cr in the previous year. Standalone PAT swung to a profit of ₹13.42Cr from a loss of ₹27.81Cr in the previous year. EBITDA Margin improved to 22.1% from -45.8%. The board also approved the re-appointment of three Independent Directors and the Internal Auditor, along with the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

Financials Positive

2026-05-25 21:39

The Board of Directors of Entero Healthcare Solutions Limited approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026, with an unmodified auditor opinion. Key decisions included the re-appointment of three Non-Executive Independent Directors and the Internal Auditor, allotment and grant of shares/options under the Employee Stock Option Plan 2023, and the announcement of the 8th Annual General Meeting on August 19, 2026. The company also announced the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

Financials Negative

2026-05-25 21:33

Standalone Revenue ₹3,482.41 Million vs ₹4,086.70 Million (▼14.8% YoY). Standalone EBITDA loss narrowed from ₹774.27 Million in the previous year to ₹672.07 Million. Standalone PAT ₹268.75 Million vs ₹191.81 Million (▲40.1% YoY). EBITDA Margin -19.3% vs -18.9% (▼36bps). The PAT increase was significantly influenced by a reduction in exceptional items from ₹470.81 Million to ₹44.97 Million.

Financials Positive

2026-05-25 21:29

Entero Healthcare Solutions Limited reported Standalone Revenue of ₹78.93Cr vs ₹72.30Cr (▲9.17% YoY) for the quarter ended March 31, 2026. EBITDA stood at ₹-13.54Cr vs ₹-59.02Cr (▲77.06% YoY, becoming less negative). PAT shifted from a loss of ₹-27.81Cr to a profit of ₹13.42Cr. EBITDA Margin improved from -81.63% to -17.15% (▲6448 bps). The board also approved re-appointment of Independent Directors and Internal Auditor, ESOP allotments/grants, scheduled the 8th AGM on August 19, 2026, and approved the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

Financials Positive

2026-05-25 21:29

Standalone Revenue ₹78.93 Cr vs ₹72.30 Cr (▲9.17% YoY), EBITDA -₹13.54 Cr vs -₹11.94 Cr (▼13.37% YoY), PAT ₹13.42 Cr vs -₹27.81 Cr (▲148.25% YoY, from loss to profit). EBITDA Margin -17.15% vs -16.51% (▼64bps).

Financials Positive

2026-05-25 21:29

Entero Healthcare Solutions reported standalone Q4 FY26 results: Revenue ₹789.32 Million vs ₹723.02 Million (▲9.2% YoY), EBITDA loss significantly reduced from ₹590.21 Million to ₹135.36 Million, and PAT turned profitable at ₹134.16 Million compared to a loss of ₹278.06 Million YoY. EBITDA Margin improved from -81.63% to -17.15% (▲6448bps). The board also approved re-appointments of Independent Directors and the Internal Auditor, allotment of ESOP shares, a fresh ESOP grant, the 8th AGM date, and the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

Financials Positive

2026-05-25 21:19

Entero Healthcare Solutions Limited reported its Standalone Financial Results for the quarter ended March 31, 2026. Standalone Revenue was ₹789.32 Million vs ₹723.02 Million (▲9.17% YoY). EBITDA improved from a loss of ₹590.21 Million in Q4 FY25 to a loss of ₹135.36 Million in Q4 FY26. Net Profit (PAT) improved significantly from a loss of ₹278.06 Million in Q4 FY25 to a profit of ₹134.16 Million in Q4 FY26. EBITDA Margin improved from -81.63% to -17.15% (▲6448 bps YoY). The board also approved re-appointments of Independent Directors and Internal Auditor, allotment and grant of ESOPs, details for the 8th AGM, and the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.

Financials Positive

2026-05-25 21:17

Standalone Revenue from operations ₹789.32Mn vs ₹723.02Mn (▲9.2% YoY). EBITDA improved from a loss of (₹590.21Mn) to a loss of (₹135.36Mn) YoY. PAT turned profitable at ₹134.16Mn vs a loss of (₹278.06Mn) YoY. EBITDA Margin improved from -81.6% to -17.2% (▲6448bps).

Financials Positive

2026-05-25 21:09

Consolidated Revenue ₹6,591.21Cr vs ₹5,095.78Cr (▲29.35% YoY), EBITDA ₹285.19Cr vs ₹211.05Cr (▲35.13% YoY), PAT ₹145.84Cr vs ₹107.43Cr (▲35.75% YoY). EBITDA Margin 4.33% vs 4.14% (▲19bps). The Board also approved re-appointment of Independent Directors and Internal Auditor, allotment and grant of ESOPs, an acquisition, and announced the 8th AGM.

Business Update Neutral

2026-05-21 18:23

Entero Healthcare Solutions Limited announced an earnings call to discuss its audited financial results for the quarter and year ended March 31, 2026. The call is scheduled for May 26, 2026, at 12:00 PM IST, and will be attended by the company's management including the MD & CEO, Whole Time Director & COO, and Group CFO.

Business Update Positive

2026-05-06 19:33

Entero Healthcare Solutions Limited announced the approval of the Scheme of Amalgamation between Chethana Pharma Distributors Private Limited and CPD Pharma Private Limited (Transferor Companies) with Rada Medisolutions Private Limited (Transferee Company). The Ministry of Corporate Affairs confirmed the scheme on April 17, 2026, with an effective date of April 15, 2025. This strategic amalgamation is expected to lead to increased operational efficiencies, economies of scale, reduction in overheads and compliance costs, and simplification of the group structure.

ENTERO

Entero Healthcare Solutions Limited

Price Chart

Filing History

Unlock Full History